News Headlines Article

Costly Turing drug gets competition
San Diego Union-Tribune

Turing Pharmaceuticals sparked nationwide outrage and government investigations when it raised the cost of a generic drug used for AIDS and cancer from $13.50 to $750 a capsule.

Today, a San Diego biomedical company introduced a competitor to that drug that sells for $1 a capsule. Moreover, the company, Imprimis Pharmaceuticals, plans to compete against other manufacturers who sell generic drugs far above their cost. Like Daraprim, these drugs tend to be used in niche markets that don’t attract much competition.

Turing’s drug, Daraprim, is a brand-name formulation of the generic drug pyrimethamine. Turing’s CEO, Martin Shkreli, gained notoriety last month when his company acquired the drug and raised the cost by 5,000 percent.